OMX Helsinki — S&P 500 — DAX — NASDAQ 100 — STOXX 600 — EUR/USD — EUR/SEK — BTC/USD — ETH/USD — Euribor 3 kk — Euribor 12 kk —
Bioretec Q3’25: Necessary revisions ahead
Sijoittaminen ja talous

Bioretec Q3’25: Necessary revisions ahead

Inderes 13.11.2025 16 min

In connection with its Q3 business review, Bioretec shed light on its situation and the commercial challenges of the RemeOs product family. The company is seeking new commercial momentum through recruitment and revisions to its distribution model. Further, the company is preparing a strategy update, which is to be launched by the end of the year. Bioretec's CEO Sarah Hubar-Fisher…

Innohub TV

Katso tämä sisältö myös Innohub TV:ssä

Avaa Innohub TV
Avaa tekoälyavustajan chat. Chat ladataan vasta, kun avaat sen.